Johnson & Johnson’s Oncology Segment Thrives with Darzalex and Carvykti, Offsetting Stelara Decline

Darzalex Sales:
Johnson & Johnson's multiple myeloma drug Darzalex saw significant growth, with sales exceeding $3 billion in the third quarter of 2024, a 25.4% year-over-year increase.

Carvykti Performance:
Carvykti, a CAR-T therapy for multiple myeloma, surged almost 88% in sales during the third quarter, contributing to J&J's strong oncology performance.

Stelara Decline:
Despite strong oncology sales, J&J's immunosuppressive drug Stelara faced a 6.6% decline in revenue due to biosimilar competition.

Full-Year Guidance:
J&J raised its full-year operational sales guidance to $89.4 billion to $89.9 billion, driven by the success of Darzalex and Carvykti.

Clinical Trial Success:
Recent Phase III trials showed Carvykti linked to a 45% reduction in the risk of death and Darzalex Faspro to a 61% improvement in minimal residual disease-negativity, further boosting their prospects.